Recurrence distance analysis for clinical target volume optimization in glioblastoma.

Patrick L Y Tang, Marion Smits, Erik D van Werkhoven, Remi A Nout, Esther A H Warnert, Alejandra Méndez Romero

Abstract read

In one paragraph

Article in Clinical and translational radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Patrick L Y TangBrain Tumor Center, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, Netherlands.

Marion SmitsBrain Tumor Center, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, Netherlands.

Erik D van WerkhovenDepartment of Radiotherapy, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, Netherlands.

Remi A NoutDepartment of Radiotherapy, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, Netherlands.

Esther A H WarnertBrain Tumor Center, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, Netherlands.

Alejandra Méndez RomeroBrain Tumor Center, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To analyze the pattern of failure in patients with glioblastoma through recurrence distance analysis, and to evaluate the feasibility of reduced and personalized clinical target volume (CTV-)margins. Methods: This study included 201 patients with IDH-wildtype glioblastoma who received standard chemoradiation between 2012 and 2022 and subsequently developed tumor recurrence. From these patients, clinical variables, radiotherapy treatment plans, and imaging data were collected. The recurrence distance was defined as the minimum isotropic expansion from the gross tumor volume (GTV) required to encompass 80% of the recurrence volume (RD Results: Median time between the last radiotherapy fraction and progressive disease was 6.8 months (IQR: 4.1-11.8 months). The median RD Conclusion: This work highlights the potential of reduced CTV-margins in patients with glioblastoma, supporting further prospective evaluation.

Indexed as

Clinical target volumeGlioblastomaPattern of failurePrecision medicineRadiotherapyRecurrence distance

Identifiers

PMID42633158

DOI10.1016/j.ctro.2026.101258

PMCPMC13499103

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.